Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics is viewed favorably because its lead asset, veligrotug, has shown differentiated phase III efficacy in active and chronic TED, including meaningful improvements in proptosis, CAS, and diplopia versus teprotumumab, supporting best-in-class potential. The commercial opportunity also looks attractive: Lumvoa was FDA approved on June 26th, reached 95% of about 2,000 core prescribers by July 31st, and early KOL feedback suggests payer access is improving as physicians adopt it for new-start patients. Further upside comes from a broader TED platform, including elegrobart with q8w subcutaneous dosing and an expanding pipeline, while the chronic TED market remains underpenetrated with only <5% treated by Tepezza.

Viridian Therapeutics is facing a negative fundamental setup because its lead TED franchise still has to prove durable, broad uptake in a market constrained by hearing-loss fears, recurrence concerns, and payer friction, with access issues like the lack of a permanent J-code and academic formulary delays limiting near-term adoption. Although KOL feedback shows some early Lumvoa interest, the commercial opportunity is still narrow and uneven, and the company’s dependence on a single disease area leaves execution highly exposed to regulatory and clinical setbacks. Financially, 2Q26 showed heavy burn with $72m in R&D, $55m in SG&A, and a $127m net loss, even after ending with $982m in cash, while a failure of veligrotug could leave the stock near its net cash value.